Overview
The linked studies administered kisspeptin-10. They include human hormone-response experiments and animal physiology studies. Other kisspeptin forms remain separately identified in the source library.[1] A hormone response is a measured endpoint, not a substitute for a demonstrated fertility or other clinical outcome. Animal findings and studies of another kisspeptin form are not interchangeable with these experiments.[1] The sections below distinguish measured findings from broader benefit claims and identify the information needed to interpret formulation, timing, and safety. A result remains attached to the population and intervention in which it was observed.
Benefits
This guide links 8 study records for Kisspeptin-10, but the presence of records is not itself an assessment of clinical benefit. A useful benefit claim needs an identifiable outcome, an appropriate comparison, and a description of who or what was studied. Laboratory activity, a biomarker response, and an improvement in symptoms should be assessed separately. Until the relevant results and limitations have been evaluated, this guide does not assign an effectiveness grade or translate a proposed use into an established benefit.
Safety
This Kisspeptin-10 guide does not yet provide a complete clinical safety assessment for a specific formulation and use. Such an assessment would need the exposure, route, participant characteristics, adverse events, and duration of follow-up from the relevant primary studies. Missing safety information cannot be interpreted as an absence of risk, and a reported event needs context before causation is assigned. Findings from one setting should remain separate from claims about another product, population, or combination.
Contraindications
The evidence summarized on this Kisspeptin-10 page is not sufficient to construct a complete contraindication list for clinical use. A study’s inclusion and exclusion criteria describe its selected participants, but they do not determine suitability for everyone outside that study. Interpreting a potential contraindication requires the exact product, intended use, health condition, and supporting evidence. This section therefore leaves unanswered suitability questions explicit instead of turning unstudied circumstances into either permission or a categorical clinical rule.
Interactions
This guide does not establish an interaction profile for Kisspeptin-10 with other peptides, medicines, or supplements. To evaluate a particular combination, the relevant evidence would need to identify the coadministered substances, formulation, route, and measured effects. Results for ingredients studied separately cannot determine whether combining them changes benefit, exposure, or harm. Related stack pages distinguish those ingredient findings from direct combination evidence and keep any unresolved interaction questions visible.
Forms & dosing
A validated dosing recommendation for Kisspeptin-10 cannot be inferred from the material currently summarized in this guide. When study records report an amount or concentration, that value belongs to the specific preparation, route, schedule, and experimental setting described in the source. Laboratory concentrations and human treatment regimens should remain separately identified. This page will not convert an isolated reported number into a consumer dose, a cycle, or a protocol for a different formulation or combination.
Results & stopping
This Kisspeptin-10 guide does not establish a general time to benefit or what happens after treatment stops. Those questions require a defined outcome, repeated measurements, and follow-up that extends beyond the intervention when persistence is being assessed. A pharmacological response during exposure would answer a different question from a sustained improvement in symptoms or function. Any future timeline should therefore state exactly what changed, when it was measured, and whether the study actually observed participants after discontinuation.
Product quality
The studies attached to a topic do not, by themselves, validate the quality of a commercial Kisspeptin-10 product. Evaluating a particular preparation requires information about its identity, composition, batch, and intended route, with testing appropriate to the claim being made. A supplier’s label cannot establish that the contents match a research intervention. This guide keeps product characterization separate from clinical effectiveness and does not endorse a vendor or finished product on the basis of an ingredient study.
Status
This page does not provide a verified, product-specific regulatory determination for Kisspeptin-10. Approval, research use, and availability need to be distinguished for the exact preparation, indication, and jurisdiction being considered. A publication establishes that an experiment was reported; it does not by itself establish authorization to market a product. Regulatory conclusions should be added only with a dated primary agency source, while research findings remain tied to the intervention actually investigated.
Evidence
These assessments describe confidence in a specific outcome for the population and formulation actually studied. Select an outcome or source count to inspect the supporting sources, methods, and limitations before applying a finding to a broader claim. Research on an individual ingredient is kept separate from evidence about a complete stack, and laboratory findings are distinguished from clinical outcomes. An unassessed question remains unresolved; it should not be read as evidence of either effectiveness or ineffectiveness. How we grade evidence.
| Outcome, finding and study design | Evidence certainty | Sources |
|---|---|---|
No outcome assessment is available for this guide yet. Source records below have not been synthesized into an assessment of benefit or safety. Inspect the available research | ||
Research Feed
Studies
Open a study to read its findings and limits, then explore the source passages and PDF details. Numbered citations link to References below.
Dynamic modulation of LH secretion by continuous kisspeptin infusion in healthy men
Direct comparison of the effects of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men
Selected passages
Analytical methods Serum LH and FSH levels were measured at all time points using automated chemiluminescent immunoassays (Abbott Diagnostics, Maidenhead, UK).
Direct_comparison_of_the_effects_of_intravenous_kisspeptin_10_kisspeptin_26089302_PMC4507333.pdf · PDF page 4
A single-blinded 3 h continuous intravenous infusion of gelofusin (vehicle), kisspeptin-10 (0.10, 0.30 or 1.00 nmol/kg/h), kisspeptin-54 (0.10, 0.30 or 1.00 nmol/ kg/h) or GnRH (0.10, 0.30 or 1.00 nmol/kg/h) was commenced at time 60 min and continued until 240 min (n = 5 subjects per group; see Table II for dose allocation of subjects).
Direct_comparison_of_the_effects_of_intravenous_kisspeptin_10_kisspeptin_26089302_PMC4507333.pdf · PDF page 3
main results and the role of chance: Serum LH and FSH levels were ∼3-fold higher during GnRH infusion when compared with kisspeptin-10 and ∼2-fold higher when compared with kisspeptin-54 [mean area under the curve serum LH during infusion (in hours times international units per litre, h.IU/l): 10.81 ± 1.73, 1.0 nmol/kg/h kisspeptin-10; 14.43 ± 1.27, 1.0 nmol/kg/h kisspeptin-54; 34.06 ± 5.18, 1.0 nmol/kg/h GnRH, P < 0.001 versus kisspeptin-10, P < 0.01 versus kisspeptin-54].
Direct_comparison_of_the_effects_of_intravenous_kisspeptin_10_kisspeptin_26089302_PMC4507333.pdf · PDF page 1
Hypothalamic-Pituitary-Ovarian Axis Reactivation by Kisspeptin-10 in Hyperprolactinemic Women With Chronic Amenorrhea
Kisspeptin and neurokinin B interactions in modulating gonadotropin secretion in women with polycystic ovary syndrome
Kisspeptin Restores Pulsatile LH Secretion in Patients with Neurokinin B Signaling Deficiencies: Physiological, Pathophysiological and Therapeutic Implications
Kisspeptin signaling in the amygdala modulates reproductive hormone secretion
Kisspeptin Signalling in the Hypothalamic Arcuate Nucleus Regulates GnRH Pulse Generator Frequency in the Rat
The Vasoactive Potential of Kisspeptin-10 in the Peripheral Vasculature
FAQs
What can this guide currently establish about Kisspeptin-10?
This guide links 8 study records for Kisspeptin-10, but the presence of records is not itself an assessment of clinical benefit. A useful benefit claim needs an identifiable outcome, an appropriate comparison, and a description of who or what was studied. Laboratory activity, a biomarker response, and an improvement in symptoms should be assessed separately. Until the relevant results and limitations have been evaluated, this guide does not assign an effectiveness grade or translate a proposed use into an established benefit.
Do reported study amounts establish a dosing recommendation?
A validated dosing recommendation for Kisspeptin-10 cannot be inferred from the material currently summarized in this guide. When study records report an amount or concentration, that value belongs to the specific preparation, route, schedule, and experimental setting described in the source. Laboratory concentrations and human treatment regimens should remain separately identified. This page will not convert an isolated reported number into a consumer dose, a cycle, or a protocol for a different formulation or combination.
Update History
Evidence and review status
- Recorded source check
- Subsequent substantive evidence update
- No later update is recorded for Kisspeptin-10.
- Independent clinical review
- Pending; this selected-source guide is AI-assisted.
A source-check date is not an exhaustive literature-search cutoff or an independent approval. Adding a paper to the catalogue does not mean its findings have been incorporated into an outcome assessment.
Read the editorial methodReferences
1 sources
- Direct_comparison_of_the_effects_of_intravenous_kisspeptin_10_kisspeptin_26089302_PMC4507333.pdf (Accessed 2026-10-04)Primary research · See study record for population and routeReview status · PendingSave study
